A blood test for early cancer detection being developed by diagnostics firm Grail has failed to meet its primary objective in a significant study conducted in partnership with England’s National Health Service, the company announced on Thursday. This setback raises questions about the viability of Grail’s technology in a competitive market increasingly focused on early cancer detection.
Grail’s test, known as Galleri, has been positioned as a leading innovation in the diagnostics field, with the potential to identify multiple cancer types through a simple blood draw. Despite its current market presence, selling 185,000 tests in 2025 and generating $136.8 million in revenue, the absence of FDA approval casts a shadow over its future prospects. The recent study results may hinder Grail’s ability to secure further investment and market confidence.
The immediate impact was evident as the company’s shares plummeted 47% in after-hours trading, reflecting investor concerns about the implications of this failed study on Grail’s long-term strategy and market position.
Use the database as your supply chain compass →
